A phase 3b, randomized, double blind, controlled study evaluating the efficacy and safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis subjects, homozygous for F508del mutation - VX18-445-109

Project Details

StatusActive
Effective start/end date1/10/1930/09/21

Funding

  • Vertex: AUD10,194.00
  • Vertex: AUD30,362.00